A Surrogate Marker Profile for PML/RARα Expressing Acute Promyelocytic Leukemia and the Association of Immunophenotypic Markers with Morphologic and Molecular Subtypes

Cytometry Part B - Clinical Cytometry

Volumn 59, Issue 1, 2004, Pages 1-9

  Paietta, Elisabeth ^a,g   Goloubeva, O ^b   Neuberg, D ^b   Bennett, J M ^c   Gallagher, R ^d   Racevskis, J ^a   Dewald, G ^e   Wiernik, P H ^a   Tallman, M S ^f  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d ALBERT EINSTEIN CANCER CENTER   (United States)

^e MAYO CLINIC   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g Our L M Cancer Ctr Immunol Lab   (United States)

Author keywords

APL; Multiparameter flow cytometry; PML RAR ; Surrogate immunophenotype; Transcript isoforms

Indexed keywords

CD11B ANTIGEN; CD133 ANTIGEN; CD18 ANTIGEN; CD2 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; HLA DR ANTIGEN; HYBRID PROTEIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PROMYELOCYTIC LEUKEMIA PROTEIN; STEM CELL FACTOR RECEPTOR; T LYMPHOCYTE ANTIGEN;

ADULT; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CELL STRUCTURE; DISEASE MARKER; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RELIABILITY;

ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CHROMOSOME ABERRATIONS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PREDICTIVE VALUE OF TESTS; RECEPTORS, RETINOIC ACID; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 2342541801     PISSN: 15524949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Paietta E, Neuberg D, Bennett JM, Dewald G, Rowe JM, Cassileth PA, Cripe L, Tallman MS, Wiernik PH. Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials. Leukemia 2003;17:1544-1550.
2. Paietta E. Immunobiology of acute leukemia. In: Wiernik P, Dutcher J, Goldman J, Kyle R, editors. Neoplastic diseases of the blood, 4th edition. Cambridge, UK: Cambridge University Press; 2003. p 194-231.
3. Hrušak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002;16:1233-1258.
4. Piedras J, López-Karpovitch X, Cárdenas R. Light scatter and immunophenotypic characteristics of blast cells in typical acute promyelocytic leukemia and its variants. Cytometry 1998;32:286-290.
5. Paietta E. Expression of cell surface antigens in APL. In: Tallman MS, editor. Bailliere's best practice & research: clinical haematology. Acute promyelocytic leukemia. Edinburgh, UK: Harcourt Publishers; 2003. p 369-385.
6. De Rossi G, Avvisati G, Coluzzi S, Fenu S, Lo Coco F, Lopez M, Nanni M, Pasqualetti D, Mandelli F. Immunological definition of acute promyelocytic leukemia (FAB M3): a study of 39 cases. Eur J Haematol 1990;45:168-171.
7. Lo Coco F, Avvisati G, Diverio D, Biondo A, Pandolfi PP, Alcalay M, De Rossi G, Petti MC, Cantù-Rajnoldi A, Pasqualetti D, Nanni M, Fenu S, Frontani M, Mandelli F. Rearrangements of the RAR-α gene in acute promyelocytic leukemia: correlations with morphology and immunophenotype. Br J Haematol 1991;78:494-499.
8. Erber WN, Asbahr H, Rule SA, Scott CS. Unique immunophenotype of acute promyelocytic leukemia as defined by CD9 and CD68 antibodies. Br J Haematol 1994;88:101-104.
9. Paietta E, Andersen J, Gallagher R, Bennett J, Yunis J, Cassileth P, Rowe J, Wiernik PH. The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia 1994;8:1108-1112.
10. Orfao A, Chillón MC, Bortoluci AM, López-Berges MC, Garcia-Sanz R, Gonzalez M, Tabernero MD, Garcia-Marcos MA, Rasillo AI, Hernandez-Rivas J, San Miguel JF. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML/RARα gene rearrangements. Haematologica 1999;84:405-412.
11. Kaleem Z, Crawford E, Pathan H, Jasper L, Covinsky MA, Johnson LR, White G. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med 2003;127:42-48.
12. Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, Cassileth P, Wiernik PH. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994;8:968-973.
13. Scott AA, Head DR, Kopecky KJ, Appelbaum FR, Theil KS, Grever MR, Chen I-M, Whittaker MH, Griffith BB, Licht JD, Waxman S, Whalen MM, Bankhurst AD, Richter LC, Grogan TM, Willman CL. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood 1994;84:244-255.
14. Paietta E, Gallagher RE, Wiernik PH. Myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as FAB-M3 acute myeloid leukemia [Correspondence]. Blood 1994;84:2824-2825.
15. Murray CK, Estey E, Paietta E, Howard RS, Edenfield WJ, Pierce S, Mann KP, Bolan C, Byrd JC. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 1999;17:293-297.
16. Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, Boccuni P, Di Noto R, Pane F, Annunziata M, Schiavone EM, De Simone M, Guglielmi C, Del Vecchio L, Lo Coco F. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans retinoic acid and chemotherapy. J Clin Oncol 2000;18:1295-1300.
17. Buss DH, Powell BL, Pettenati MJ, Lyerly ES, Beaty MW, Woodruff RD, Cruz JM, Hurd DD. The HLA-DR negative/CD34 negative phenotype in acute myeloid leukemias other than acute promyelocytic leukemia [Abstract #4448]. Blood 2002;100:232b.
18. Wetzler M, McElwain BK, Stewart CC, Blumenson L, Mortazavi A, Ford LA, Slack JL, Barcos M, Ferrone S. HLA-DR antigen-negative acute myeloid leukemia. Leukemia 2003;17:707-715.
19. Gallagher RE, Willman CL, Slack JL, Andersen JW, Li Y, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH. Association of PML/RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997;90:1656-1663.
20. Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985;103:620-625.
21. Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C. A variant form of hypergranular promyelocytic leukemia. Br J Haematol 1980;44:169-170.
22. Paietta E, Andersen J, Racevskis J, Ashigbi M, Cassileth P, Wiernik PH. Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Blood Rev 1995;9:47-52.
23. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic B, Greenberg PL. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999;93:787-795.
24. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. New York: Chapman and Hall; 1984.
25. Drach D, Zhao S, Drach J, Andreeff M. Low incidence of MDR1 expression in acute promyelocytic leukemia. Br J Haematol 1995;90:369-374.
26. Paietta E, Andersen J, Yunis J, Rowe JM, Cassileth PA, Tallman MS. Acute myeloid leukaemia expressing the leucocyte integrin CD11b - a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Br J Haematol 1998;100:265-272.
27. Di Noto R, Schiavone EM, Ferrara F, Manzo C, Lo Pardo C, Del Vecchio L. All-trans retinoic acid promotes a differential regulation of adhesion molecules on acute myeloid leukemia blast cells. Br J Haematol 1994;88:247-255.
28. Paietta E. Adhesion molecules in acute myeloid leukemia [Comment]. Leuk Res 1996;20:795-798.
29. Chan JY-H, Watt SM. Adhesion receptors on hematopoietic progenitor cells. Br J Haematol 2001;112:541-557.
30. Paietta E. Immunophenotypic peculiarities of APL. Proceedings of the 2nd International Symposium on Acute Promyelocytic Leukemia - A Curable Disease; 1997. p 10.
31. Di Noto R, Lo Pardo C, Schiavone EM, Manzo C, Vacca C, Ferrara F, Del Vecchio L. Stem cell factor receptor (c-kit, CD117) is expressed on blast cells from most immature types of acute myeloid malignancies but is also a characteristic of a subset of acute promyelocytic leukemia. Br J Haematol 1996;92:562-564.
32. Schwartz S, Heinecke A, Zimmermann M, Creutzig U, Schoch C, Harbott J, Fonatsch C, Löffler H, Büchner T, Ludwig W-D, Thiel E. Expression of the c-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. Leuk Lymphoma 1999;34:85-94.
33. Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, Warrell RP Jr. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994;84:3843-3849.
34. Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 2001;25:1-12.
35. Grimwade D, Outram SV, Flora R, Ings SJ, Pizzey AR, Morilla R, Craddock CF, Linch DC, Solomon E. The T-lineage-affiliated CD2 gene lies within an open chromatin environment in acute promyelocytic leukemia cells. Cancer Res 2002;62:4730-4735.
36. Grignani F, Valtieri M, Gabbianelli M, Gelmetti V, Botta R, Luchetti L, Masella B, Morsilli P, Pelosi E, Samoggia P, Pelicci PG, Peschle C. PML/RARα fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood 2000;96:1531-1537.
37. Claxton DF, Reading CL, Nagarajan L, Tsujimoto Y, Andersson BS, Estey E, Cork A, Huh YO, Trujillo J, Deisseroth AB. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood 1992;80:582-586.
38. Biondi A, Luciano A, Bassan R, Mininni D, Specchia G, Lanzi E, Castagna S, Cantù-Rajnoldi A, Masera G, Barbui T, Rambaldi A. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint. Leukemia 1995;9:1461-1466.
39. Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantú-Rajnoldi A, Biondo A, Cocito MG, Del Vecchio L, Tabilio A, Avvisati G, Basso G, Lo Coco F. Immunophenotype of adult and childhood acute promyelocytic leukemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol 1998;102:1035-1041.
40. Exner M, Thalhammer R, Kapiotis S, Mitterbauer G, Knöbl P, Haas OA, Jäger U, Schwarzinger I. The "typical" immunophenotype of acute promyelocytic leukemia (APL-M3): does it prove true for the M3-variant? Cytometry 2000;42:106-109.
41. Foley R, Soamboonsrup P, Carter RF, Benger A, Meyer R, Walker I, Wan Y, Patterson W, Orzel A, Sunisloe L, Leber B, Neame PB. CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. Am J Hematol 2001;67:34-41.
42. Knapp W, Strobl H, Majdic O. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. Cytometry 1994;18:187-198.
43. Sun Y, Kim SH, Ramesh KH, Cannizzaro L, Paietta E, Warrell RP Jr, Gallagher, RE. Immortalization of acute promyelocytic leukemia (APL) cell culture AP-1060 associated with altered growth factor response [Abstract #4378]. Blood 2001;98:173b.
44. Maslak P, Miller WH Jr, Heller G, Scheinberg DA, Dmitrovsky E, Warrell RP Jr. CD2 expression and PML/RAR-α transcripts in acute promyelocytic leukemia [Correspondence]. Blood 1993;81:1666.
45. Gallagher RE, Li Y-P, Rao S, Paietta E, Andersen J, Etkind P, Bennett JM, Tallman MS, Wiernik PH. Characterization of acute promyelocytic leukemia cases with PML/RARα break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood 1995;86:1540-1547.
46. Slack JL, Willman CL, Andersen JW, Li Y-P, Viswanatha DS, Bloomfield CD, Tallman MS, Gallagher RE. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARa isoform: results from Intergroup protocol 0129. Blood 2000;95:398-403.
47. González M, Barragán E, Bolufer P, Chillón C, Colomer D, Borstein R, Calasanz MI, Gómez-Casares MT, Villegas A, Marugán I, Román J, Martín G, Rayón C, Debén G, Tormo M, Díaz-Mediavilla J, Esteve J, González-San Miguel J, Rivas C, Pérez-Equiza K, García-Sanz R, Capote FJ, Ribera JM, Arias J, León A, Sanz MA. Pretreatment characteristics and clinical outcome of acute promyelocytic leukemia patients according to the PML-RARα isoforms: a study of the PETHEMA group. Br J Haematol 2001;114:99-103.